Japan · Delayed Price · Currency is JPY Mani, Inc. Earnings Call Transcripts
Fiscal Year 2026
-
DIA-BUR sales in China rebounded to 87% of pre-recall levels, and record Q3 sales were achieved, driven by strong growth in China and India. Full-year guidance was raised, with conservative Q4 profit assumptions and further upside possible if risks do not materialize.
-
Strong first-half results with record sales and operating income, driven by robust recovery in China, strategic transformation in Germany, and new product launches. Outlook remains positive but cautious due to geopolitical uncertainties, with dividend plans unchanged.
-
Record first quarter sales and operating income were driven by rapid DIA-Burs recovery in China, strong eyeless needle growth, and strategic moves including a new China factory and a stake in iRIS EYE. Operating margin reached 28.8%, with positive outlook for further recovery and expansion.
Fiscal Year 2025
-
FY2025 saw a significant profit decline due to the DIA-BURS recall in China, but strong growth in surgical and eyeless needle segments. FY2026 guidance anticipates a 9.4% sales increase, with recovery in DIA-BURS and new product launches driving future growth.
-
Third quarter FY 2025 results were heavily impacted by the voluntary recall in China, leading to revised full-year forecasts and a significant profit reduction. Strong growth in surgical and eyeless needle segments offset dental segment declines, with recovery expected in FY 2026.
-
Voluntary recall in China led to a JPY 800 million sales hit, but strong Surgical and Eyeless Needle Segments offset the impact, keeping Q2 FY2025 results in line with forecasts. Full-year guidance and dividends remain unchanged.
-
Management is accelerating growth plans, targeting JPY 50B in sales and 16% ROE by FY2029, with new products and global expansion as key drivers. Strategic investments, operational improvements, and proactive risk management underpin the outlook.